 |
Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy CME DisclosuresRelease Date: May 23, 2008; Valid for credit through May 23, 2009 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Identify the most common type of brain tumor
- List the most likely primary sources of brain metastases
- Describe the most likely clinical presentations of brain metastases
- Identify factors that affect
approaches to the management of brain metastases
- Describe the most common and effective treatment approaches to brain metastases
Authors and Disclosures Matthew G. Ewend, MD
Disclosure: Matthew G. Ewend, MD, has disclosed that he has received grant or research support from MGI PHARMA, Inc.
David E. Morris, MD
Disclosure: David E. Morris, MD, has disclosed that he has been a scientific advisor and consultant for Radiosurgery Centers Corporation. Dr. Morris has received research support from Genentech, and has stock in Synarc and Anesiva. Lisa A. Carey, MD
Disclosure: Lisa A. Carey, MD, has disclosed that she has been a consultant for, and is on the speakers'
bureau and advisory board for Genentech, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, and sanofi-aventis. Dr. Carey has also disclosed that she has received grant or research support from Genentech, GlaxoSmithKline, Bristol-Myers Squibb, and Boehringer Ingelheim. She has also received research funding from Boehringer Ingelheim. Alim M. Ladha, MD
Disclosure: Alim M. Ladha, MD, has disclosed no relevant financial
relationships. Steven Brem, MD
Disclosure: Steven Brem, MD, has disclosed that he has received grant or research support from MGI PHARMA, Inc., and is on the speakers' bureau and advisory boards for MGI PHARMA, Inc. and Schering-Plough Corporation. Désirée Lie, MD, MSEd
Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial
relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
